Ignite Creation Date:
2024-05-06 @ 7:36 AM
Last Modification Date:
2024-10-26 @ 11:50 AM
Study NCT ID:
NCT02568267
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-21
First Post:
2015-10-02
Brief Title:
Basket Study of Entrectinib RXDX-101 for the Treatment of Patients With Solid Tumors Harboring NTRK 123 Trk ABC ROS1 or ALK Gene Rearrangements Fusions
Sponsor:
Hoffmann-La Roche
Organization:
Hoffmann-La Roche
Study Overview
Official Title:
An Open-Label Multicenter Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK123 ROS1 or ALK Gene Rearrangements
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
True
If Expanded Access, NCT#:
NCT03066661
Has Expanded Access, NCT# Status:
NO_LONGER_AVAILABLE
Acronym:
STARTRK-2
Brief Summary:
This is an open-label multicenter global Phase 2 basket study of entrectinib RXDX-101 for the treatment of patients with solid tumors that harbor an NTRK123 ROS1 or ALK gene fusion Patients will be assigned to different baskets according to tumor type and gene fusion
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| GO40782 | OTHER | Hoffman-La Roche | None |
| 2015-003385-84 | EUDRACT_NUMBER | None | None |